| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| UNI - EN REPORT No | 113 | / | 2017 | ||||||||
| Date of issue: | 2017-12-08 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| Notification from Rompharm Company OOD | |||||||||||
| Official market - legal basis | |||||||||||
| art. 56. 1. 2 of Act on Public Offering. | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| Sopharma AD notifies that on 8 December 2017 the Company received two notifications from Rompharm Company OOD for the sale of shares from the capital of Sopharma AD. The first notification concerns the sale of 5 000 000 shares, as a result of which the share of Rompharm Company OOD in the capital of Sopharma AD fell under 15% to 12.88%. The date of the registration of the transaction with the Central Depository is 7 December 2017. The first notification concerns the sale of 4 685 000 shares, as a result of which the share of Rompharm Company OOD in the capital of Sopharma AD fell under 10% to 9.41%. The date of the registration of the transaction with the Central Depository is 8 December 2017. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| notification 113-rompharm.pdf | Notification from Rompharm Company OOD | ||||||||||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2017-12-08 | Ognian Donev | Executive director | |||
notification 113-rompharm.pdf